Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
$121M later, Langer-backed Selecta raises $70M more from its IPO
10 years ago
Financing
Antifungal player F2G banks $60M, eyes IPO in leadup to a PhIII trial
10 years ago
Financing
R&D
Sean Parker finds a big role to play in cancer R&D: The disruptive billionaire
10 years ago
People
R&D
Savara hunts cash after doubling down on late-stage respiratory drugs
10 years ago
Pharma
Novartis takes aim at a slate of blockbusters with cheaper biosimilars
10 years ago
Pharma
Circassia shares crumble as PhIII flop blights the sector once again
10 years ago
R&D
Epizyme says it’s excited by PhII data, but there’s plenty to fret about
10 years ago
R&D
What is Endpoints?
10 years ago
Editor's note
First page
Previous page
1194
1195
1196
1197
